Paradigm Biocapital Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,390,077	Closed	-$34.7M	–	35
2023 Q3	$34.7M	Sell	2,390,077 -34,055	-1%	-$644K	2.36%	17
2023 Q2	$50.7M	Buy	2,424,132 +149,620	+7%	+$3.12M	3.92%	12
2023 Q1	$48M	Buy	2,274,512 +320,000	+16%	+$7.96M	4.55%	10
2022 Q4	$49.7M	Buy	1,954,512 +869,370	+80%	+$20.3M	5.84%	7
2022 Q3	$26.1M	Buy	1,085,142 +208,986	+24%	+$4.69M	3.48%	14
2022 Q2	$16.9M	Buy	876,156 +174,800	+25%	+$2.91M	3.36%	12
2022 Q1	$12.2M	Buy	701,356 +248,265	+55%	+$4.18M	3.22%	14
2021 Q4	$9.92M	Buy	+453,091	New	+$8.37M	2.83%	15

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Paradigm Biocapital Advisors's SNDX Position: Q4 2023 in Review

Paradigm Biocapital Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q4 2023, closing a stake of 2,390,077 shares — an estimated $34.7M sold.

Paradigm Biocapital Advisors first reported a position in SNDX in Q4 2021 and held it in 8 quarters. The position peaked at $50.7M in Q2 2023. 177 funds tracked by Wall St. Rank hold SNDX as of Q4 2023.

Paradigm Biocapital Advisors reported no remaining Syndax Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Paradigm Biocapital Advisors sold 2,390,077 Syndax Pharmaceuticals shares in Q4 2023, an estimated $34.7M.
Paradigm Biocapital Advisors first reported a position in Syndax Pharmaceuticals in Q4 2021 and held it in 8 quarters.
Paradigm Biocapital Advisors's Syndax Pharmaceuticals position peaked at $50.7M in Q2 2023.
177 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2023.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.